Novavax Investor Relations https://ir.novavax.com/ Novavax to Participate in BofA Securities 2026 Health Care Conference https://novavax.investorroom.com/2026-05-07-Novavax-to-Participate-in-BofA-Securities-2026-Health-Care-Conference <p>Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 13, 2026 Time: 3:00...</p> 05/07/2026 https://novavax.investorroom.com/2026-05-07-Novavax-to-Participate-in-BofA-Securities-2026-Health-Care-Conference Novavax to Report First Quarter 2026 Financial Results on May 6, 2026 https://novavax.investorroom.com/2026-04-29-Novavax-to-Report-First-Quarter-2026-Financial-Results-on-May-6,-2026 <p>Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May 6, 2026. Details of...</p> 04/29/2026 https://novavax.investorroom.com/2026-04-29-Novavax-to-Report-First-Quarter-2026-Financial-Results-on-May-6,-2026 Novavax Announces Entering into a License Agreement with Pfizer https://novavax.investorroom.com/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer <p>Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the...</p> 01/20/2026 https://novavax.investorroom.com/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study https://novavax.investorroom.com/2025-07-24-Novavaxs-H5N1-Vaccine-Candidate-Demonstrates-Immunogenicity-in-Preclinical-Study <p>Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single...</p> 07/24/2025 https://novavax.investorroom.com/2025-07-24-Novavaxs-H5N1-Vaccine-Candidate-Demonstrates-Immunogenicity-in-Preclinical-Study Novavax Announces Changes to Board of Directors https://novavax.investorroom.com/2025-03-11-Novavax-Announces-Changes-to-Board-of-Directors <p>James Young, PhD retires as Chair of the Board, Margaret McGlynn, RPh, appointed John Shiver, PhD appointed to board of directors GAITHERSBURG, Md., March 11, 2025 /PRNewswire/ -- Novavax, Inc....</p> 03/11/2025 https://novavax.investorroom.com/2025-03-11-Novavax-Announces-Changes-to-Board-of-Directors